{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-004262","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.919008+00:00","generated_at":"2026-06-07T00:03:52.689817+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Candel Therapeutics CFO Jason Amello resigns; Charles Schoch named interim CFO","bullets":["Jason A. Amello resigned as CFO effective Jan 12, 2024, to pursue another opportunity.","Board appointed Charles Schoch as interim CFO, effective Jan 12, 2024.","Schoch had served as VP of Finance and Corporate Controller since March 2023.","Schoch's annual base salary increased to $325,000 as interim CFO.","Schoch is a CPA with prior experience at Corbus Pharmaceuticals and PwC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-004262","json":"https://secwatch.observer/filing/0000950170-24-004262.json","markdown":"https://secwatch.observer/filing/0000950170-24-004262.md","text":"https://secwatch.observer/filing/0000950170-24-004262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/cadl-20240112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:03:52.689817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3174297d1a","claim":"Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..","evidence_excerpt":"Jason A. Amello resigned from his position as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f75119b333","claim":"Charles Schoch was appointed as interim Chief Financial Officer at Candel Therapeutics, Inc..","evidence_excerpt":"unanimously appointed Charles Schoch as the Company’s interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}